facebook button AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Sponsor: Aravive, Inc.

AVB500-OC-004: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer.

For patients with ovarian, or fallopian tube, or primary peritoneal high-grade serous adenocarcinoma with progression of disease within 6 months of completion of the most recent line of platinum-containing chemotherapy.

For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly at 631-675-5075.